 Study PCYC-1116-CA is an open-label, multicenter extension of Study PCYC 1115-CA RESONATETM-2, the parent study, and it will run concurrently with the parent study. A patient will be transferred to PCYC-1116-CA after Independent Review Committee IRC confirmation of disease progression PD in the parent study or at closure of the parent study by the sponsor, whichever comes first. 